期刊
NATURE REVIEWS DISEASE PRIMERS
卷 2, 期 -, 页码 1-22出版社
NATURE PORTFOLIO
DOI: 10.1038/nrdp.2016.80
关键词
-
资金
- Japan Agency for Medical Research and Development
- Australian National Health and Medical Research Council Principal Research Fellowship
- Victorian Government's Operational Infrastructure Support Program
- Wellcome Trust Centre for Mitochondrial Research, Newcastle University Centre for Ageing and Vitality (Biotechnology and Biological Sciences Research Council)
- Wellcome Trust Centre for Mitochondrial Research, Newcastle University Centre for Ageing and Vitality (Medical Research Council (MRC))
- MRC Centre for Neuromuscular Disease
- MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (UK)
- Lily Foundation
- UK National Institute for Health Research (NIHR) Biomedical Research Centre in Age and Age Related Diseases
- UK NHS Specialist Commissioners 'Rare Mitochondrial Disorders of Adults and Children' Service
- European Research Council
- Sigrid Juselius Foundation
- Academy of Finland
- MRC
- MRC [MC_UP_1002/1, G1100540, G0400074, G0502157, G0900652] Funding Source: UKRI
- Medical Research Council [G0502157, G0400074, MC_UP_1002/1, G1100540, G0900652] Funding Source: researchfish
Mitochondrial diseases are a group of genetic disorders that are characterized by defects in oxidative phosphorylation and caused by mutations in genes in the nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) that encode structural mitochondrial proteins or proteins involved in mitochondrial function. Mitochondrial diseases are the most common group of inherited metabolic disorders and are among the most common forms of inherited neurological disorders. One of the challenges of mitochondrial diseases is the marked clinical variation seen in patients, which can delay diagnosis. However, advances in next-generation sequencing techniques have substantially improved diagnosis, particularly in children. Establishing a genetic diagnosis allows patients with mitochondrial diseases to have reproductive options, but this is more challenging for women with pathogenetic mtDNA mutations that are strictly maternally inherited. Recent advances in in vitro fertilization techniques, including mitochondrial donation, will offer a better reproductive choice for these women in the future. The treatment of patients with mitochondrial diseases remains a challenge, but guidelines are available to manage the complications of disease. Moreover, an increasing number of therapeutic options are being considered, and with the development of large cohorts of patients and biomarkers, several clinical trials are in progress.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据